Brokerages predict that CONMED Corporation (NASDAQ:CNMD) will report $211.29 million in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for CONMED Corporation’s earnings, with estimates ranging from $208.48 million to $213.40 million. CONMED Corporation posted sales of $204.09 million in the same quarter last year, which suggests a positive year over year growth rate of 3.5%. The business is scheduled to report its next earnings results on Wednesday, February 7th.

According to Zacks, analysts expect that CONMED Corporation will report full-year sales of $211.29 million for the current fiscal year, with estimates ranging from $780.27 million to $787.30 million. For the next fiscal year, analysts expect that the business will report sales of $805.68 million per share, with estimates ranging from $800.00 million to $810.20 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover CONMED Corporation.

CONMED Corporation (NASDAQ:CNMD) last issued its quarterly earnings data on Thursday, November 2nd. The medical technology company reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.01. The company had revenue of $190.10 million for the quarter, compared to analyst estimates of $187.13 million. CONMED Corporation had a return on equity of 8.40% and a net margin of 1.99%. The business’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.41 earnings per share.

Several equities analysts have issued reports on CNMD shares. KeyCorp reaffirmed a “hold” rating on shares of CONMED Corporation in a report on Friday, August 25th. Needham & Company LLC reaffirmed a “buy” rating and set a $57.00 price objective on shares of CONMED Corporation in a report on Friday, September 1st. Zacks Investment Research lowered CONMED Corporation from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $46.00 price objective on shares of CONMED Corporation in a report on Friday, November 3rd. Finally, TheStreet raised CONMED Corporation from a “c+” rating to a “b-” rating in a report on Thursday, August 3rd. Two analysts have rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $50.33.

In other news, EVP Luke A. Pomilio sold 10,020 shares of the stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $53.57, for a total transaction of $536,771.40. Following the completion of the sale, the executive vice president now owns 44,472 shares in the company, valued at $2,382,365.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Luke A. Pomilio sold 12,429 shares of the stock in a transaction dated Tuesday, November 7th. The stock was sold at an average price of $50.63, for a total transaction of $629,280.27. Following the sale, the chief financial officer now owns 45,486 shares of the company’s stock, valued at approximately $2,302,956.18. The disclosure for this sale can be found here. Insiders have sold 51,812 shares of company stock valued at $2,654,756 in the last quarter. Insiders own 2.62% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. Epoch Investment Partners Inc. lifted its position in CONMED Corporation by 2.1% in the third quarter. Epoch Investment Partners Inc. now owns 232,576 shares of the medical technology company’s stock valued at $12,203,000 after purchasing an additional 4,839 shares during the period. Pinebridge Investments L.P. lifted its position in CONMED Corporation by 30.1% in the third quarter. Pinebridge Investments L.P. now owns 27,316 shares of the medical technology company’s stock valued at $1,433,000 after purchasing an additional 6,313 shares during the period. OxFORD Asset Management LLP acquired a new stake in CONMED Corporation in the third quarter valued at about $294,000. Schwab Charles Investment Management Inc. lifted its position in CONMED Corporation by 4.6% in the third quarter. Schwab Charles Investment Management Inc. now owns 174,980 shares of the medical technology company’s stock valued at $9,182,000 after purchasing an additional 7,642 shares during the period. Finally, Wells Fargo & Company MN lifted its position in CONMED Corporation by 34.8% in the third quarter. Wells Fargo & Company MN now owns 40,224 shares of the medical technology company’s stock valued at $2,111,000 after purchasing an additional 10,394 shares during the period. Hedge funds and other institutional investors own 98.74% of the company’s stock.

WARNING: This news story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/11/14/conmed-corporation-cnmd-expected-to-announce-quarterly-sales-of-211-29-million.html.

CONMED Corporation (NASDAQ CNMD) opened at $50.24 on Tuesday. The stock has a market capitalization of $1,390.83, a PE ratio of 28.45, a price-to-earnings-growth ratio of 3.14 and a beta of 0.66. CONMED Corporation has a twelve month low of $39.74 and a twelve month high of $54.47. The company has a current ratio of 2.56, a quick ratio of 1.49 and a debt-to-equity ratio of 0.84.

About CONMED Corporation

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.

Get a free copy of the Zacks research report on CONMED Corporation (CNMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CONMED Corporation (NASDAQ:CNMD)

Receive News & Ratings for CONMED Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED Corporation and related companies with MarketBeat.com's FREE daily email newsletter.